Esther S Oh1,2,3,4, Tracy D Vannorsdall2,5, Ann M Parker6,7. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Johns Hopkins University School of Nursing, Baltimore, Maryland. 5. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. Outcomes After Critical Illness and Surgery Research Group, Johns Hopkins University School of Medicine, Baltimore, Maryland.
As of June 7, 2021, there are more than 168 000 000 survivors of COVID-19
worldwide. Approximately 72% of survivors report at least 1 symptom persisting 30 days
or more beyond the acute illness, and symptoms frequently persist even among patients
who were relatively young and never hospitalized.[1] Commonly reported symptoms include fatigue, shortness of breath,
anxiety, depression, insomnia, and cognitive impairment.[1] Given the emerging public health crisis
represented by this burden of survivorship, there is an urgent need for understanding
postacute sequelae of SARS-CoV-2 (PASC).Although much has been written about PASC, there is still little known about the
long-term cognitive sequelae of COVID-19. The cohort study by Søraas et
al[2] is one of the largest
cohort studies reporting on long-term cognitive symptoms of COVID-19. In this study, 13
001 individuals who were tested largely because they had symptoms suspicious for
SARS-CoV-2 infection or individuals who were untested and randomly selected from the
general population in Norway. The individuals who had been tested for SARS-CoV-2 were
tested between February 1 and April 15, 2020, and none were hospitalized. Participants
completed an online questionnaire including demographics, comorbidities, health-related
quality of life, and memory problems at baseline and approximately 8 months later. After
adjusting for confounders, SARS-CoV-2 test positivity was associated with an almost 5
times higher likelihood of reporting subjective memory problems at 8-month
follow-up.Current understanding of cognitive sequelae of COVID-19 is still largely limited
to individuals who required hospitalization. Among hospitalized patients, objective
deficits have been reported in verbal fluency, attention, working memory, processing
speed, executive functioning, learning, and memory, with no clear pattern of cognitive
weakness emerging across studies.[3,4] Importantly, survivors of critical
illness commonly experience cognitive impairment, with more than a third having scores
on cognitive testing consistent with moderate traumatic brain injury at 1 year
follow-up.[5] Hence,
understanding overlapping and distinct features of cognitive impairment following
critical illness, and COVID-19 is a key research priority.In recent years, there has been mounting evidence that subjective memory concerns
are associated with increased risk of future cognitive impairment. In long-term studies
with more than 4 years of follow-up, older adults with subjective memory concerns have
increased risk of progression to mild cognitive impairment (27%) or dementia
(14%).[6] However, while
subjective cognitive concerns may portend cognitive decline in some older individuals,
it remains too early to determine if this is the case following COVID-19. At present,
limited data from COVID-19 survivors suggest subjective concerns are not associated with
concurrent objective cognitive deficits.[3,4,7]Poor cognitive performance may be associated with severity of mental and physical
impairment. A 2021 observational study[8]
of 1077 adults discharged with diagnosis of COVID-19 in UK identified 4 different
recovery phenotypes (mild, moderate, severe, and very severe) using cluster analysis of
mental, physical, and cognitive health based on patient reported outcomes and tests of
physical performance at the 5-month follow up. Mental health (eg, depression, anxiety,
etc) and physical health outcomes were associated with each other within each cluster,
while cognitive function, measured by Montreal Cognitive Assessment, remained
independent. Importantly, the “moderate” cluster, which had the most
pronounced cognitive impairment, also had the highest mean age among the 4
clusters.[8] Therefore,
examination of subjective memory concerns and more in-depth evaluation of objective
cognitive outcomes in the context of mental and physical health outcomes will be
essential in determining the nature and trajectory of cognitive impairment following
COVID-19. In addition, the trajectory of individuals with subjective memory concerns may
differ by age, and a closer cognitive follow-up may be warranted in older
individuals.Limitations of the study by Søraas et al[2] include the low overall response rate (24%) and
potential bias in both participation and responses to survey questions introduced by
knowing their SARS-CoV-2 test results. Additionally, there are no data on race or
ethnicity, and the results are from a single country in Scandinavia.To advance the current knowledge of cognitive impairment among COVID-19
survivors, longer prospective cohort studies that include individuals from different
races and ethnicities are needed to determine symptom persistence, and more importantly,
the potential association between subjective cognitive impairment and rate of objective
cognitive impairment compared with age-, sex-, and education-adjusted norms. Moreover,
the functional consequences of persistent cognitive dysfunction among individuals who
may have been at the height of their work productivity before SARS-CoV-2 infection is an
important area in need of further investigation. Finally, ongoing efforts to understand
the underlying biological mechanism of the effect of SARS-CoV-2 on the brain will be
important in identifying those at high risk of developing subsequent cognitive
impairment.
Authors: P P Pandharipande; T D Girard; J C Jackson; A Morandi; J L Thompson; B T Pun; N E Brummel; C G Hughes; E E Vasilevskis; A K Shintani; K G Moons; S K Geevarghese; A Canonico; R O Hopkins; G R Bernard; R S Dittus; E W Ely Journal: N Engl J Med Date: 2013-10-03 Impact factor: 91.245
Authors: Edith L Graham; Jeffrey R Clark; Zachary S Orban; Patrick H Lim; April L Szymanski; Carolyn Taylor; Rebecca M DiBiase; Dan Tong Jia; Roumen Balabanov; Sam U Ho; Ayush Batra; Eric M Liotta; Igor J Koralnik Journal: Ann Clin Transl Neurol Date: 2021-03-30 Impact factor: 4.511
Authors: Rachael A Evans; Hamish McAuley; Ewen M Harrison; Aarti Shikotra; Amisha Singapuri; Marco Sereno; Omer Elneima; Annemarie B Docherty; Nazir I Lone; Olivia C Leavy; Luke Daines; J Kenneth Baillie; Jeremy S Brown; Trudie Chalder; Anthony De Soyza; Nawar Diar Bakerly; Nicholas Easom; John R Geddes; Neil J Greening; Nick Hart; Liam G Heaney; Simon Heller; Luke Howard; John R Hurst; Joseph Jacob; R Gisli Jenkins; Caroline Jolley; Steven Kerr; Onn M Kon; Keir Lewis; Janet M Lord; Gerry P McCann; Stefan Neubauer; Peter J M Openshaw; Dhruv Parekh; Paul Pfeffer; Najib M Rahman; Betty Raman; Matthew Richardson; Matthew Rowland; Malcolm G Semple; Ajay M Shah; Sally J Singh; Aziz Sheikh; David Thomas; Mark Toshner; James D Chalmers; Ling-Pei Ho; Alex Horsley; Michael Marks; Krisnah Poinasamy; Louise V Wain; Christopher E Brightling Journal: Lancet Respir Med Date: 2021-10-07 Impact factor: 30.700
Authors: Arne Søraas; Ragnhild Bø; Karl Trygve Kalleberg; Nathalie C Støer; Merete Ellingjord-Dale; Nils Inge Landrø Journal: JAMA Netw Open Date: 2021-07-01
Authors: Biykem Bozkurt; Sandeep R Das; Daniel Addison; Aakriti Gupta; Hani Jneid; Sadiya S Khan; George Augustine Koromia; Prathit A Kulkarni; Kathleen LaPoint; Eldrin F Lewis; Erin D Michos; Pamela N Peterson; Mohit K Turagam; Tracy Y Wang; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2022-06-23 Impact factor: 27.203
Authors: Biykem Bozkurt; Sandeep R Das; Daniel Addison; Aakriti Gupta; Hani Jneid; Sadiya S Khan; George Augustine Koromia; Prathit A Kulkarni; Kathleen LaPoint; Eldrin F Lewis; Erin D Michos; Pamela N Peterson; Mohit K Turagam; Tracy Y Wang; Clyde W Yancy Journal: Circ Cardiovasc Qual Outcomes Date: 2022-06-23
Authors: Vardan Nersesjan; Lise Fonsmark; Rune H B Christensen; Moshgan Amiri; Charlotte Merie; Anne-Mette Lebech; Terese Katzenstein; Lia E Bang; Jesper Kjærgaard; Daniel Kondziella; Michael E Benros Journal: JAMA Psychiatry Date: 2022-05-01 Impact factor: 25.911
Authors: Michelle Mendanha Mendonça; Kellen Rosa da Cruz; Denise da Silva Pinheiro; Gean Carlos Alves Moraes; Patricia Maria Ferreira; Marcos Luiz Ferreira-Neto; Eduardo Sérgio da Silva; Reggiani Vilela Gonçalves; Gustavo Rodrigues Pedrino; James O Fajemiroye; Carlos Henrique Xavier Journal: Hematol Transfus Cell Ther Date: 2022-01-25